Immunotech Laboratories, Inc. (IMMB) today released company updates for shareholders and Investors

Immunotech Laboratories Inc. , A Nevada Corporation,(IMMB), is pleased to announce that the financials for the company have been completed and are currently being audited. Blaine Nabors VP of Business Development today said Immunotech’s financials are now complete and now is in the hands of our Auditor, Travis Green, DKM…

Immunotech Laboraties, Inc. Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status

Immunotech Laboratories, Inc. (IMMB) today announced the company signed an agreement with The Lebrecht Group, a professional law corporation, to provide legal services for Immunotech and to upgrade the company to OTC:BB fully reporting current status. Immunotech Founder, President and Chief Science Officer Harry Zhabilov today commented, “This step will help assure…

Immunotech Laboratories Inc. Announces Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients

Immunotech Laboratories, Inc. (IMMB) Pursuant to significantly positive results with its patient population targeting full blown AIDS patients, the company has completed numerous clinical contracts with Mexican hospitals to initiate a full blown effort of clinical trial protocol preparation for its HIV/AIDS Vaccine drug candidate. The successful outcome of these…

Case study: Disminution of plasma viral load and cultured HIV-infected peripheral blood mononuclear cells

HIV AIDS Rev, 2004; Disminution of plasma viral load and cultured HIV-infected peripheral blood mononuclear cells in non-responding patients treated with two calf thymus nuclear proteins and conventional antiretrovirals. J. Jacobo Ayala-Gaytán1, Eduardo R. Zapata de la Garza1, Salvador B. Valdovinos-Chávez2, Leticia Navarro-Marmolejo3, Javier Vargas Villarreal3,Herminia G. Martínez-Rodríguez4, Rebeca Palacios-Corona3, Ricardo M. Cerda-Flores5, Hampar…

Immunotech Laboratories, Inc. signed a contract with partner in Bulgaria to register a company called Immunotech Laboratories B.G. LLC

Immunotech Laboratories, Inc. (IMMB) signed a contract with strategic partners in Bulgaria to register a company called Immunotech Laboratories B.G. LLC. Immunotech Laboratories, Inc. will own 49% of the Bulgarian subsidiary. The goal of Immunotech Laboratories BG is to conduct pre-clinical testing, clinical trials phase I, phase II, and phase…

What’s up with Viral Load?

One glaring problem with the HIV/AIDS hypothesis is that researchers have been unable to find enough HIV (actual virus) in people who test positive to explain compromised health. Even among patients suffering from the most severe AIDS-defining illnesses, HIV is never detected in quantities that could cause depletion of immune…

Inactivated Pepsin Fraction (IPF) Recognizes Viral Antigens

Most people infected with hepatitis C virus (HCV) do not have any acute signs or symptoms of hepatitis. They usually remain unaware that they have been infected during the first 10‐20 years, unless they have a blood test. They will usually be found to have some elevations of liver enzymes in their…

Immunotech Laboratories Agreement with Viral Genetics Inc.

In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims…

IPF – Scientific Abstract (presented on the 5th European Conference on Clinical And Social Research and AIDS and Drugs )

Below we show you the investigation that we presented on the 5th European Conference on Clinical And Social Research and AIDS and Drugs about IPF as a treatment for HIV.   IPF displays significant Antiviral activity in vitro without provoking the presentation of resistant profiles of minority subspecies Jeannie Gibbs,…